ArticleAge and ageing2021
Neuropsychiatric symptoms in early stage of Alzheimer's and non-Alzheimer's dementia, and the risk of progression to severe dementia.
Article in Age and ageing, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Predictors for survival in patients with Alzheimer's disease: a large comprehensive meta-analysis.Translational psychiatry · 2024Pooled it
- Proton pump inhibitor use and risk of dementia in a population-based cohort study.Scientific reports · 2026Article
- Neuropsychiatric symptoms in preclinical and clinically manifest dementia: clusters and their health determinants.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- An Ultra-Brief Informant Questionnaire for Case Finding of Cognitive Impairment Across Diverse Literacy: Diagnostic Accuracy Study.JMIR aging · 2026Article
- A normative calculator for MoCA domain scores: proxy for Z-scores of conventional neuropsychological tests.Alzheimer's research & therapy · 2025Article
- PENSIEVE-AI a brief cognitive test to detect cognitive impairment across diverse literacy.Nature communications · 2025Article
- Cognitive therapies and their impact on neuropsychiatric symptoms in mild cognitive impairment or dementia: a scoping review.Frontiers in psychology · 2025Review
- Recent Advances in Therapeutics for the Treatment of Alzheimer's Disease.Molecules (Basel, Switzerland) · 2024Review
- Progress on early diagnosing Alzheimer's disease.Frontiers of medicine · 2024Review
- Examining the non-linear effects of education on Alzheimer's and non-Alzheimer's disease: Sex-stratified analysis of 17,671 older persons.Social science & medicine (1982) · 2024Article
- The neural basis of neuropsychiatric symptoms in Alzheimer's disease.Frontiers in aging neuroscience · 2024Review
- Neuropsychiatric features in a multi-ethnic population with Alzheimer disease and mild cognitive impairment.International journal of geriatric psychiatry · 2023Article
- An Update on Apathy in Alzheimer's Disease.Geriatrics (Basel, Switzerland) · 2023Review
- The reporting of neuropsychiatric symptoms in electronic health records of individuals with Alzheimer's disease: a natural language processing study.Alzheimer's research & therapy · 2023Article
- Experiences and understanding of apathy in people with neurocognitive disorders and their carers: a qualitative interview study.Age and ageing · 2023Article
- Effects of the DICE Method to Improve Timely Recognition and Treatment of Neuropsychiatric Symptoms in Early Alzheimer's Disease at the Memory Clinic: The BEAT-IT Study.Journal of Alzheimer's disease : JAD · 2023Article
- The recognition and management of neuropsychiatric symptoms in early Alzheimer's disease: a qualitative study among Dutch memory clinic physicians.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society · 2022Article
- Systemic and central nervous system neuroinflammatory signatures of neuropsychiatric symptoms and related cognitive decline in older people.Journal of neuroinflammation · 2022Article
- Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer's disease.Alzheimer's research & therapy · 2022Review
- The VTA dopaminergic system as diagnostic and therapeutical target for Alzheimer's disease.Frontiers in psychiatry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
backgroundNeuropsychiatric symptoms (NPSs) in early dementia have been suggested to predict a higher risk of dementia progression. However, the literature is not yet clear whether the risk is similar across Alzheimer's dementia (AD) and non-Alzheimer's dementia (non-AD), as well as across different NPSs. This study examined the association between NPSs in early dementia and the risk of progression to severe dementia, specifically in AD and non-AD, as well as across various NPSs.
methodThis cohort study included 7,594 participants who were ≥65 years and had early dementia (global Clinical Dementia Rating [CDR] = 1). Participants completed Neuropsychiatric-Inventory-Questionnaire at baseline and were followed-up almost annually for progression to severe dementia (global CDR = 3) (median follow-up = 3.5 years; interquartile range = 2.1-5.9 years). Cox regression was used to examine progression risk, stratified by AD and non-AD.
resultsThe presence of NPSs was associated with risk of progression to severe dementia, but primarily in AD (HR 1.4, 95% confidence interval [CI]: 1.1-1.6) and not in non-AD (HR 0.9, 95% CI: 0.5-1.5). When comparing across various NPSs, seven NPSs in AD were associated with disease progression, and they were depression, anxiety, apathy, delusions, hallucinations, irritability and motor disturbance (HR 1.2-1.6). In contrast, only hallucinations and delusions were associated with disease progression in non-AD (HR 1.7-1.9).
conclusionsNPSs in early dementia-especially among individuals with AD-can be useful prognostic markers of disease progression. They may inform discussion on advanced care planning and prompt clinical review to incorporate evidence-based interventions that may address disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.